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Abstract.
BACKGROUND: Skin melanocytes can give rise to benign and malignant neoplasms. Discrimination of an early melanoma
from an unusual/atypical benign nevus can represent a significant challenge. However, previous studies have shown that in
contrast to benign nevi, melanoma demonstrates pervasive chromosomal aberrations.
OBJECTIVE: This substantial difference between melanoma and benign nevi can be exploited to discriminate between
melanoma and benign nevi.
METHODS: Array-comparative genomic hybridization (aCGH) is an approach that can be used on DNA extracted from
formalin-fixed paraffin-embedded (FFPE) tissues to assess the entire genome for the presence of changes in DNA copy number. In
this study, high resolution, genome-wide single-nucleotide polymorphism (SNP) arrays were utilized to perform comprehensive
and detailed analyses of recurrent copy number aberrations in 41 melanoma samples in comparison with 21 benign nevi.
RESULTS: We found statistically significant copy number gains and losses within melanoma samples. Some of the identified
aberrations are previously implicated in melanoma. Moreover, novel regions of copy number alterations were identified, revealing
new candidate genes potentially involved in melanoma pathogenesis.
CONCLUSIONS: Taken together, these findings can help improve melanoma diagnosis and introduce novel melanoma thera-
peutic targets.
Keywords: Array comparative genomic hybridization, melanoma, FFPE
1. Background1
In the United States, skin cancer is the most common2
of all cancers [1]. Most cases of skin cancer are non-3
melanoma skin cancer. In fact, melanoma accounts for4
less than 2% of skin cancer cases [1]. Melanoma is5
a cancer that arises from the malignant transforma-6
tion of epidermal melanocytes, pigment-synthesizing7
cells of the skin. When melanoma escapes early de-8
tection, it becomes one of the most aggressive and9
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highly lethal forms of cancer. Although it accounts 10
for the minority of skin cancers, a large majority 11
(75%) of skin cancer related-deaths are accounted for 12
by melanoma [1,2]. The incidence and mortality of 13
melanoma has increased dramatically in the last few 14
decades [3]. The American Cancer Society estimates 15
that about 73,870 people in United States will be diag- 16
nosed with melanoma in 2015 and about 9,940 people 17
are expected to die from the disease. Importantly, the 18
5-year survival rate of melanoma depends on the stage 19
of the disease when it is diagnosed. It can be as high 20
as 98% when the melanoma is detected early before 21
it spreads to the lymph nodes or other organs. When 22
melanoma reaches the lymph nodes, the 5-year sur- 23
vival rate drops to 62%, and to 15% when melanoma 24
spread to other organs [2]. Different factors are re- 25
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sponsible for an increased risk of melanoma devel-26
opment. These factors include physical characteristics27
such as red hair, blue eyes, light complexion and pres-28
ence of pigmented lesions. Moreover, environmental29
factors such as sun exposure are associated with an30
increased risk of melanoma. Yet, the genetic factors31
and a strong family history of the disease are the most32
important factors contributing to an increased risk of33
melanoma [4,5].34
The pigment-producing cells, melanocytes, can give35
rise to benign (melanocytic nevi) or malignant (mela-36
noma) neoplasms. Early diagnosis of melanoma still37
the most effective way for long term survival and sav-38
ing melanoma patients’ lives from the disease [6].39
In the majority of cases, dermatopathologists can40
correctly diagnose and differentiate a melanocytic41
nevus from a malignant melanoma. However, der-42
matopathologists are aware of the diagnostic difficul-43
ties of a subset of melanocytic tumors that cannot be44
easily classified as benign or melanoma. These tu-45
mors have ambiguous histopathological features that46
overlap between melanocytic nevi and melanoma,47
where some benign melanocytic nevi, due to secondary48
changes, show unusual attributes that are more associ-49
ated with melanoma diagnosis. Therefore, the pathol-50
ogy of melanocytic neoplasms remains as one of the51
most challenging and controversial areas in diagnos-52
tic histopathology [7]. The uncertainty and discor-53
dance among expert dermatopathologists in diagnos-54
ing melanocytic neoplasms have been shown in sev-55
eral studies [8–14]. The diagnostic uncertainty and56
the ambiguity of some melanocytic tumors results in57
melanoma misdiagnosis, which in turn can lead to58
melanoma overdiagnosis accompanied with increase59
in medical costs and unnecessary surgeries and stress.60
Conversely, melanoma underdiagnoses results in neg-61
ligence of a lethal disease [6] that would have been im-62
minently curable if resected earlier.63
Histopathological examination of hematoxylin and64
eosin (H&E)-stained tissue sections remains the main65
approach for evaluating melanocytic tumors. How-66
ever, due to the histopathological ambiguity of some67
melanocytic neoplasms, molecular diagnostic tech-68
niques have emerged in the field of dermatopathol-69
ogy as ancillary tests that can help in the diagnosis of70
melanoma. These molecular tests have shown promise71
in improving the differential diagnosis of melanoma.72
One of these molecular diagnostic techniques that has73
been used intensively in melanoma diagnosis is im-74
munohistochemical staining for melanocytic markers75
such as Melan-A (A103), S-100 and HMB-45 [15–17].76
More recently, cytogenetic analyses have been devel- 77
oped and become popular methods in the area of dis- 78
tinguishing melanoma from benign nevi. For instance, 79
using fluorescence in situ hybridization (FISH) as- 80
says as an adjunctive test in the diagnosis of ambigu- 81
ous melanocytic tumors have been increasingly uti- 82
lized in dermatopathology laboratories. Several stud- 83
ies have shown the potential of the FISH assay as a 84
successful discriminatory test that can distinguish be- 85
tween problematic melanocytic lesions [7,18–21]. Cur- 86
rently, the most commonly used FISH assay employs 87
a 4-probe panel targeting 4 loci (RREB1, MYB, cen- 88
tromere 6, and CCND1) on 2 different chromosomes. 89
The 4-probes FISH has shown a sensitivity and speci- 90
ficity of 86.7% and 95.4% respectively [18]. Recent 91
study has shown an improvement of the FISH assay by 92
incorporating new probes that target 4 different chro- 93
mosomes (CDKN2A on 9p21, RREB1 on 6p25, MYC 94
on 8q24 and CCND1 on 11q13) with increased sensi- 95
tivity and specificity to 94% and 98% respectively [7]. 96
Although the FISH assay was introduced as a di- 97
agnostic tool in the field of differential diagnosis of 98
melanoma fairly recently, the principle of developing 99
this assay was based on findings that existed over a 100
decade ago. After the emersion of comparative ge- 101
nomic hybridization as a novel technique that can 102
screen the entire genome for copy number changes 103
in one experiments in 1992 [22], several studies (by 104
Bastian and others) have revealed that the majority of 105
melanomas differ from benign nevi in their genetic 106
makeup. These studies demonstrated gain or loss of 107
specific chromosomal segments and showed that the 108
majority of melanomas harbor recurrent chromoso- 109
mal copy number aberrations. With some exceptions 110
such as in Spitz nevi, these chromosomal rearrange- 111
ments are rarely detected in melanocytic nevi [23– 112
26]. Frequent genomic alterations known to occur in 113
melanoma include gains at 1q, 6p, 7p, 7q, 8q, 17q and 114
20q in conjunction with deletions at 6q, 8p, 9p, 9q, 115
10p, 10q, 11q and 21q [23–25]. These fundamental dif- 116
ferences in the pattern of genetic alterations between 117
melanomas and benign nevi established the idea that 118
copy number variations can be diagnostically valuable 119
for histopathologically ambiguous melanocytic neo- 120
plasms. Therefore, developing diagnostic assays tar- 121
geting these genetic differences, such as FISH as- 122
says, would help improve the differential diagnosis and 123
prognosis of melanoma. 124
Utilizing CGH as a research tool has been decid- 125
edly a huge advancement in the cancer research field. 126
As previously mentioned, the use of CGH has en- 127
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hanced our knowledge of the genetic alterations oc-128
curring in melanocytic tumors. However, in melanoma129
these genetic alterations tend to be broad copy num-130
ber events spanning large genomic regions. Ratio-131
nally, the frequent existence of changes in these ge-132
nomic regions in melanoma, but not in the benign133
nevi, indicates the presence of critical melanoma-134
related genes within these regions. The task of un-135
covering such genes remains a challenge. Yet, signifi-136
cant progress in CGH technology and the development137
of newer, high-density, genome-wide single-nucleotide138
polymorphism (SNP) arrays have simplified this task139
and make it achievable. The high-resolution microar-140
rays allow for detection of more precise and smaller141
regions of specific copy number changes. The effec-142
tiveness of using these arrays in accurate identifica-143
tion of copy number alterations has been shown in144
various cancer studies [27–31]. Applying this high-145
resolution technique in melanoma has shown more de-146
tailed and recurrent amplifications and deletions of147
genomic regions containing important cancer genes.148
Among these genes are CDKN2A and PTEN in the149
statistically significant deleted regions; BRAF, EGFR150
and CCND as the most frequently amplified genes [4,151
21,32,33]. Furthermore, good examples of the ability152
of these high-resolution microarrays in revealing po-153
tential cancer genes were demonstrated in identifying154
the current melanoma biomarker MITF gene [34] and155
the melanoma metastatic gene NEDD9 as well [35].156
Therefore, these advances in array CGH technology157
have provided great opportunities to detect novel and158
previously unrecognized key driver genes that can help159
improve melanoma prognosis, diagnosis, and even aid160
development of targeted therapies.161
Here, we report our investigation for chromosomal162
aberrations that can help in the identification of ge-163
nomic targets for melanoma diagnosis and therapy. To164
detect genome-wide statistically significant copy num-165
ber events, we analyzed high-density single-nucleotide166
polymorphism (SNP) array data of 41 melanoma sam-167
ples compared with 21 benign nevi. We utilize a sta-168
tistical method called genomic identification of sig-169
nificant targets in cancer (GISTIC) that allow of de-170
tection of genomic regions that have a high proba-171
bility to contain driver cancer genes [36,37]. GISTIC172
has been actively used in different cancer studies and173
has helped in the detection of different amplified and174
deleted genes [38–42]. The 41 melanoma samples an-175
alyzed by GISTIC show 8 statistically significant am-176
plifications and 32 deletions, some of which are previ-177
ously known in melanoma.178
2. Methods 179
2.1. Specimen collection and preparation 180
Following IRB review, total of 62 specimens (41 181
melanoma plus 21 benign nevi) were selected from a 182
large archive of FFPE skin biopsies collected at a na- 183
tional dermatopathology laboratory (Dermatopathol- 184
ogy Laboratory of Central States, DLCS, Dayton, OH). 185
Patients ranged in age from 14 to 90 years (Table 1). 186
The cohort of biopsy specimens used in this study was 187
collected between 2001 and 2013, making their age 188
range between 2 and 14 years. Specimens were stored 189
in a temperature-controlled environment. Melanomas 190
were all between stages II and V, and were verified by a 191
qualified dermatopathologist. Upon review, melanoma 192
specimens with less than 60% tumor tissue (such as 193
specimens with a brisk lymphocytic infiltrate) were ex- 194
cluded from study. 195
De-identified retrospective clinical data were ob- 196
tained from clinical databases and patient health 197
records at DLCS. For all experiments, 10 μm thick sec- 198
tions were taken for each sample from paraffin blocks 199
by using a microtome with disposable blades. Care was 200
taken to avoid contamination between the specimens 201
by wearing gloves when handling the blocks, cleaning 202
the microtome after cutting a block, and using fresh 203
blades for each specimen. The sections were placed 204
in a warm water bath and then mounted on slides to 205
be air dried. The first and last slides from each block 206
were stained with H&E to verify that the region of 207
interest (consisting of cellular material) had not been 208
exhausted. Tissue was then scraped from slides us- 209
ing sterile scalpel blades into 1.5 mL microcentrifuge 210
tubes or Screw-Cap microTUBES (Covaris, Woburn, 211
MA, USA) for DNA extraction. The number of sec- 212
tions taken per sample varies between methods, as de- 213
scribed below. 214
2.2. DNA Isolation from FFPE tissues 215
DNA isolation was carried out using column-based 216
methods. Qiagen QIAamp DNA FFPE tissue kit (Qia- 217
gen, Valencia, CA, USA) or adaptive focused acoustics 218
(AFA)- based extraction using the Covaris truXTRAC 219
FFPE DNA kit (Covaris). 220
For the Qiagen method, 24 sections of 10 μm thick- 221
ness FFPE tissues were used as suggested by the man- 222
ufacturer with some modifications as follows. Deparaf- 223
finization of FFPE tissues was performed by incubat- 224
ing twice in 1 mL xylene, then in a descending con- 225
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Table 1
Clinicopathological data for specimens used in this study
# Age at diagnosis Sex Location Clark’s level Type
1 77 Male Right Arm IV Superficial spreading type
2 28 Male Right Ear I Malignant melanoma in situ
3 80 Male Forehead IV Desmoplastic type
4 75 Female Upper Back IV/V Superficial spreading type
5 21 Female Right Shoulder I Malignant melanoma in situ
6 40 Male Back IV Malignant melanoma
7 60 Female Left Leg IV Nodular spitzoid type
8 57 Female Right Arm I Malignant melanoma in situ
9 81 Male Left Auricular IV Superficial spreading type
10 93 Male Right Groin IV Nodular malignant melanoma
11 60 Female Left Leg IV Nodular spitzoid type
12 89 Male Right Shoulder III/IV Malignant melanoma
13 63 Female Right Forearm IV Superficial spreading type
14 76 Female Right Cheek IV Superficial spreading type
15 57 Male Left Arm IV Superficial spreading type
16 45 Female Left Back IV Ulcerated nodular malignant melanoma
17 60 Male Left Shin IV Spitzoid type
18 77 Male Right Elbow IV Invasive malignant melanoma
19 27 Female Right Neck IV Posterior invasive polypoid malignant melanoma
20 69 Male Left Temple IV Superficial spreading type
21 74 Male Left Neck IV Superficial spreading type
22 67 Female Right Back IV Malignant melanoma with verticle growth
23 53 Male Right Arm IV Nodular malignant melanoma
24 68 Female Left Arm I Residual malignant melanoma
25 54 Female Anterior Thigh IV Superficial spreading type
26 72 Male Right Shoulder III Superficial spreading type
27 80 Male Forehead IV Desmoplastic type
28 48 Female Right Forearm V Nodular variant
29 40 Male Back IV Malignant melanoma
30 74 Female Right Arm II Superficial spreading type
31 63 Male Back IV Superficial spreading type
32 45 Female Left Arm III Superficial spreading type
33 75 Male Right Chest III–IV Desmoplastic type
34 40 Female Upper Back III–IV Nodular type
35 85 Female Right Cheek IV/V Malignant melanoma
36 87 Male Right Cheek V Malignant melanoma
37 90 Male Left Back IV Superficial spreading type
38 55 Female Middle Back II/III Superficial spreading type
39 28 Female Left Shoulder III Invasive spitzoid malignant melanoma
40 42 Male Right Pretibial III Superficial spreading type
41 75 Male Left Back IV Melanoma with regression
42 34 Male Right Arm − Dermal nevus
43 44 Female Right Buttock − Dermal nevus
44 55 Male Left Back − Dermal nevus
45 19 Female Left Back − Dermal nevus
46 39 Male Left Neck − Dermal nevus
47 35 Male Left Flank − Dermal nevus
48 34 Female Right Neck − Dermal nevus
49 44 Male Right Groin − Dermal nevus
50 27 Female Right Back − Dermal nevus
51 62 Female Right Eyebrow − Dermal nevus
52 48 Female Left Neck − Dermal nevus
53 75 Female Left Shoulder − Dermal nevus
54 34 Female Left Deltoid − Dermal nevus
55 33 Female Right Back − Dermal nevus
56 38 Female Middle Back − Dermal nevus
57 52 Female Right Back − Dermal nevus
58 41 Female Right Neck − Dermal nevus
59 14 Female Right Shoulder − Dermal nevus
60 16 Female Left Back − Dermal nevus
61 21 Male Right Back − Dermal nevus
62 60 Female Right Neck − Dermal nevus
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centration of ethanol (100, 75%, then 50%). The tis-226
sues were then incubated in 300 μL Qiagen buffer ATL227
plus 40 μL proteinase K (20 mg/mL, 5 PRIME Inc.,228
Gaithersburg, MD, USA) for 72 hours. An additional229
30 μL proteinase K was added at 24 hours, and another230
30 μL at 48 hours. After 72 hours digestion, samples231
were washed in Qiagen DNeasy Mini Spin Columns232
with buffers AW1 and AW2. An extra wash with AW2233
buffer was used to further reduce the carry-over of234
solvents. Finally, samples were eluted in 100 μl ATE235
buffer.236
The second extraction method used adaptive fo-237
cused acoustics (AFA) technology as described pre-238
viously [43]. This was performed using FFPE tissues239
with 10 μm thickness for 8–10 sections, depending240
on the size of the tissue, to obtain approximately 5241
mg of tissue. The extraction was performed accord-242
ing to the protocol suggested by Covaris in the truX-243
TRAC FFPE DNA kit. Slides were warmed on a heat244
block to 37◦C for 30 seconds. FFPE tissues were245
then scraped from the slides, avoiding paraffin, us-246
ing Covaris SectionPicks. Sections were collected into247
Screw-Cap microTUBES by using FFPE SectionPicks248
provided by Covaris. AFA was performed per man-249
ufacturer’s instructions (“protocol C”) on a Covaris250
M220 Focused-Ultrasonicator. Homogenized tissues251
were then digested for 2 hours in Covaris proteinase K252
at 56◦C. DNA was finally isolated from lysates using253
the columns of the Covaris truXTRAC FFPE DNA kit254
and eluted in 100 μL Covaris BE buffer. When needed,255
DNA was concentrated by speedvac without heat.256
2.3. Quality control257
A Nanodrop spectrophotometer was used to quan-258
tify DNA concentration as well as determine the259
A260/A230 and A260/A280 ratios. For a more accu-260
rate quantitation, the Qubit R© dsDNA BR Assay Kit261
(Thermo Fisher Scientific, Waltham, MA) was used to262
check the concentrations of dsDNA for all samples.263
Genomic DNA fragment sizes were first estimated264
by agarose gel electrophoresis of 250 ng DNA using265
1% agarose gels (90 mM Tris – borate, 2 mM EDTA,266
1% agarose). Samples with visible DNA fragments as267
large as 23,000 base pairs (bp) were processed fur-268
ther by randomly amplified polymorphic DNA PCR269
(RAPD-PCR) to directly determine the ability of each270
sample to produce high molecular weight amplicons271
(“amplifiability”). Non-specific primers and PCR con-272
ditions (below) were used to produce multiple ampli-273
cons from each sample. Agarose gel electrophoresis274
was used to determine the range of product sizes and 275
only samples with amplicons larger than 500 bp were 276
used for microarray analysis. 277
RAPD-PCR reactions were carried out in a 20 μL 278
volume containing 25 ng DNA and using 10 μl of Go- 279
Taq 2X Green Master Mix (Promega, Madison, WI 280
USA). PCR was performed in 0.2 mL tubes in a Ge- 281
neAmp PCR System 9700 thermocycler (Life Tech- 282
nologies, Carlsbad, CA, USA). 283
Primers used for RAPD-PCR were generated by 284
Eurofins MWG Operon Inc. (Huntsville, AL, USA). 285
Sequences for the primer pairs and cycling parame- 286
ters were as follows: 5’-AATCGGGCTG-3’ and 5’- 287
GAAACGGGTG-3’, 94◦C for 2.5 minutes, then 45 cy- 288
cles of 1 minute 94◦C, 1 minute 55◦C and 2 minutes 289
72◦C, then 7 minutes 72◦C and holding at 4◦C; or 5′- 290
TGTGCCCAGTGAAGACTCAG-3’ and 5′-GAGTGA 291
GCGGAGAGGGAACT-3’, 45 cycles of 94◦ C for 1 292
minute, 35◦C for 1 minute, and 72◦C for 2 minute. 293
PCR products were resolved on 3% TBE agarose plus 294
SYBR Safe dye (Life Technologies). Gels were visu- 295
alized with a GE ImageQuant LAS-3000 camera (GE 296
Healthcare Life Sciences, Piscataway, NJ, USA). 297
2.4. Microarrays 298
DNA copy number analysis was performed by hy- 299
bridizing the extracted and qualified gDNA to Affy- 300
metrix SNP6.0 microarrays (Affymetrix, Santa Clara, 301
CA, USA). All samples passed RAPD-PCR quality 302
control. 0.5 μg of genomic DNA was processed using 303
the SNP 6.0 protocol and microarrays by Affymetrix 304
with some modifications to the standard protocol. The 305
input amount of DNA was increased from 250 ng per 306
restriction enzyme (Nsp1 and Sty1) to 500 ng each. 307
The number of PCR reactions was doubled from the 308
suggested three for Sty1 and four for Nsp1 to six for 309
Sty1 and eight for Nsp1. It is important to note that the 310
number of reactions was increased; the number of cy- 311
cles in each reaction remained the same. The additional 312
PCR reactions were combined as in the standard proto- 313
col. PCR cleanup was performed using isopropanol ex- 314
traction (refer to Affymetrix User Bulletin 2: Improve- 315
ments to step 7 of the SNP Assay 6.0, PCR cleanup us- 316
ing an isopropanol precipitation method, P/N 702968 317
Rev. 1). Hybridization and scanning of the arrays fol- 318
lowed the manufacturer’s protocol to generate SNP6.0 319
CEL files. 320
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2.5. Data analysis321
The Copy Number Inference Pipeline is a method in322
GenePattern from the Broad Institute (Massachusetts323
Institute of Technology, Cambridge, MA) that takes324
Affymetrix SNP6 CEL files and process them in a325
pipeline consisting of different modules to generate326
segmented copy number calls for each sample [44,45].327
DNA copy number was estimated probe set-wise by328
comparing the normalized signal from 41 melanoma329
samples to data generated from 21 benign samples that330
were used as a reference. Briefly, the pipeline first uses331
SNPFileCreator_SNP6 module to normalize all of the332
SNP arrays by adjusting the raw intensity values from333
the SNP6 array so that they can be compared with other334
arrays. The second step is to convert intensity measure-335
ments into copy number calls by using the CopyNum-336
berInference module. Then the copy number noise337
was calculated and copy number calls were de-noised338
with the RemoveCopyNumberOutliers module that re-339
moves probes that are outliers, which have radically340
different copy number calls than their hg19-adjacent341
neighbors. The Tangent normalization algorithm then342
reduces the noise further by subtracting out variation343
seen in a pre-defined set of a panel of more than344
3000 blood normals from the Cancer Genome Atlas345
(TCGA). This exclusion of the germline CNVs is par-346
ticularly important for algorithms that identify somatic347
alterations that are statistically significant such as GIS-348
TIC. The copy number data then were segmented by349
using the CBS (Circular Binary segmentation) algo-350
rithm that identifies regions in the genome that, in spite351
of noise, probably have a uniform underlying copy352
number. It compresses the values from a set of adja-353
cent probes into a single value for that interval [46].354
Lastly, the segmented copy number data were analyzed355
with GISTIC to identify significant melanoma genetic356
aberrations.357
Genomic Identification of Significant targets in Can-358
cer (GISTIC2.0) is a statistical method (also within359
GenePattern) that identifies likely somatic copy num-360
ber alterations that drive cancer pathogenesis by eval-361
uating the frequency and amplitude of observed copy362
number events that are more frequent than would be363
expected by chance [36,37]. GISTIC assigns GAMP364
and GDEL scores to each locus. The G score repre-365
sents the frequency of a genetic aberration (amplifi-366
cations or deletions) seen at that locus across a set367
of samples, multiplied by the average (increase or de-368
crease) in the log2 ratio in the region of aberration.369
A peak region is reported at each statistically signifi-370
cant genomic region of aberration and known genes lo- 371
cated at that region are listed. GISTIC performs false 372
discovery rate control where G-scores are compared 373
against a null model, and regions with q-values be- 374
low 0.25 are considered statistically significant. GIS- 375
TIC analysis was performed using the default parame- 376
ters with some modifications. Based on the segmented 377
data values, we set the amplifications and deletions 378
threshold for log2 ratios to > 0.1 and < −0.3, respec- 379
tively. The segmented copy number data (in log2 ra- 380
tio) were capped to 2, where regions with log2 val- 381
ues greater than 2 are replaced with 2 and regions with 382
log2 values less than −2 are replaced with −2. The 383
confidence level used to calculate the region contain- 384
ing a driver was 99%. GISTIC also employed a length- 385
based filtering of arm-level events where all copy num- 386
ber events occupying more than 98% of a chromo- 387
some arm were removed. Using this length-based fil- 388
ter greatly increases the sensitivity of GISTIC to de- 389
tect focal events [36]. When calculating for significant 390
deletions, segments that contain a number of markers 391
less than or equal to 10 were joined to the neighboring 392
segment that is closest in copy number. The Genomic 393
coordinates were mapped to the human genome build 394
19 (http://genome.ucsc.edu). 395
3. Results and discussion 396
3.1. Amplifications identified by GISTIC 397
21q22.1 398
This region has not been shown to be amplified 399
in melanoma before. Only one gene was reported 400
in this region in our findings, which is ERG. ERG 401
“Avian v-ets erythroblastosis virus E26 oncogene” is 402
a proto-oncogene that belongs to the ETS transcrip- 403
tion factor gene family that plays a role in embry- 404
onic development, cell proliferation, angiogenesis, and 405
apoptosis [47,48]. Overexpression of ERG has been 406
found in different cancers including Ewing sarcoma, 407
acute myeloid leukemia, and meningiomas [47]. More- 408
over, the oncogenic role of ERG is prominent in the 409
TMPRSS2-ERG fusion gene in prostate cancer [49– 410
53]. These recent findings have declared the role of this 411
gene in cancer. In this study, a high focal amplification 412
targeting the ERG gene on chromosome 21 was iden- 413
tified. This focal amplification strongly suggests that 414
ERG could be an important driver gene in melanoma. 415
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11q14.1416
This region has just one gene, which is DLG2.417
DLG2 “discs, large homolog2” is a member of mem-418
brane-associated guanylate kinases family that has im-419
portant roles in tissue developments, cell-cell com-420
munications, cell polarity control, and cellular signal421
transductions [54]. A study found DLG2 was upreg-422
ulated in renal oncocytoma, a benign tumor of the423
kidney, which explains it’s potential role as an onco-424
gene [55]. Interestingly, this chromosomal location425
11q14.1 is located close to CCND1 at 11q13, an ampli-426
fied region in melanoma that is used as a FISH target427
to distinguish between melanoma and benign nevi [7].428
10q11.21429
This peak represent a focal amplification of this re-430
gion that spanned the RET gene. RET “Rearranged431
during transfection” is a proto-oncogene that encodes a432
transmembrane receptor tyrosine kinase [56–58]. RET433
has been shown to have an important role in human434
cancers [57,58], and it’s amplification and overexpres-435
sion have been reported in different types of cancers436
such as thyroid cancer [59], lung cancer [60], breast437
cancer [56], and pancreatic cancer [61]. Furthermore,438
RET has been shown to be involved in activation of439
several important signaling pathways including PI3K,440
Ras/MAPK, Jun N-terminal kinase “JNK” and PLC-441
dependent pathways [58,62].442
In melanoma, a study on human melanoma cell lines443
has showed a correlation between the expression of444
RET and melanomagenesis. Also, the study showed445
that inhibition of RET signaling suppressed all prolif-446
eration and invasion in melanoma [62]. Another study447
reported the involvement of RET in melanoma devel-448
opment in RET-mice and human melanoma cells [63].449
These two studies besides the focal region of amplifi-450
cation centered on the RET gene in our study indicate451
the potential importance of RET in melanoma. There-452
fore, our study suggest that RET could be one of the453
driver genes in melanoma tumorgenesis.454
6p24.3455
Gain of 6p is a common chromosomal imbalance in456
several human cancers, which indicate the importance457
of genes involved in this region in cancer pathogene-458
sis [64]. In melanoma, gain of 6p is one of the most459
common chromosomal abnormalities that was reported460
in several studies [5,6,25,26,35,64,65]. Identifying im-461
portant genes in this large gain still a challenge. In462
melanoma, the minimal region of 6p gain has not been463
characterized [65]. In our study, this peak at 6p24.3464
represents a partial gain of 6p (22.74 Mb). Interest- 465
ingly, several important genes in melanoma were iden- 466
tified in this peak. NEDD9, one of the main melanoma 467
metastasis genes [35], RREB1, one of the FISH assay 468
targets that is used to distinguish between melanoma 469
and benign nevi [7], and DEK, an oncogene that was 470
reported to have a dual and selective roles in prolifer- 471
ation and apoptotic resistance in melanoma [65]. An- 472
other important gene in this region is E2F3 gene, an 473
oncogene that has an important role in tumorigenesis in 474
bladder cancer [66]. Therefore, against the large back- 475
ground of 6p gain that is common in melanoma, the 476
partial gain of this part of chromosome 6p in our analy- 477
sis, with known genes in melanoma located in this part, 478
minimizes the broad gain of 6p to a smaller region that 479
is highly associated with melanoma. 480
1q31.2 481
This peak represents gain of the entire long arm of 482
chromosome 1 (1q). Gain of the long arm of chro- 483
mosome 1 represents a common genetic alteration in 484
melanoma [5,6,25,26,64]. A CGH study has shown 485
that Patients with 1q and 6p gain had a lower overall 486
survival rate in comparison with patients without these 487
gains, which implies that 1q and 6p gains could give a 488
prognostic differences [67]. Several important genes in 489
cancer, and more specifically in melanoma, are located 490
on this genomic region. This includes AKT3 [68,69], 491
MDM4 [70], and ABL2 [71]. Our study confirms that 492
gain in chromosome 1q as one of the most important 493
genetic alterations in melanoma. 494
8q24.23 495
Gain of 8q is another hallmark in melanoma that 496
was reported in many different studies [4,6,25,26,72]. 497
In our findings, the peak on chromosome 8 represent 498
high amplification of a part of the long arm of chro- 499
mosome 8, which is 8q24. A study has suggested that 500
targeting this region 8q24 by FISH assays could be a 501
useful prognostic marker in melanoma cancers [73]. A 502
later study that sought to improve the sensitivity and 503
specificity of FISH assay for discriminating melanoma 504
from nevi has confirmed and included the 8q24 re- 505
gion as one of four FISH targets with high discrimi- 506
natory power to differentiate between melanoma and 507
benign nevi [7]. The most prominent gene in this re- 508
gion is MYC, a proto-oncogene that encodes a nu- 509
clear phosphoprotein transcription factor that plays a 510
role in different cellular processes, such as prolifer- 511
ation, cell cycle progression, metabolism, differentia- 512
tion and apoptosis [74]. MYC amplification has been 513
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shown in different cancers including prostate [75] and514
breast cancer [76]. In melanoma, it has been shown that515
melanomas with gain of 8q24 have elevated cytoplas-516
mic and membranous expression of MYC in compari-517
son with melanomas without gain of 8q24, where they518
had significantly decreased MYC expression. This el-519
evated expression of MYC seems to play a role in the520
aggressive clinical behavior of melanomas [77]. This521
is another common genetic alteration in melanoma that522
is confirmed in our study.523
7p12.3 & 7p14.3524
Gain of the p arm of chromosome 7 is one of the525
most common copy number gains in melanoma [6,25,526
26,78]. On the other hand, the q arm in melanoma is527
known with the activating point mutation of the BRAF528
oncogene [79]. Although the gain of 7p is common in529
melanoma, targets in this arm still undescribed [78].530
Here, two focal amplifications were identified in our531
study, 7p12.3 and 7p14.3 regions. For the 7p12.3 re-532
gion, GISTIC has reported this region with no known533
genes, but TNS3 is the nearest known gene to that re-534
gion. Despite what gene was found here, this chromo-535
somal region has gotten much attention in cancer stud-536
ies. Amplification of this region has been reported in537
different types of cancers including amplification of538
7p12.3 in pancreatic cancer [80] and rectal cancer [81].539
Also amplifications in the 7p12 band has been shown540
in acute lymphoblastic leukemia [82] and osteosarco-541
mas [83]. The attention to this region is mainly because542
the oncogene EGFR “Epidermal growth factor recep-543
tor” is located in this band [84]. EGFR is known to play544
a role in metastasis, cellular proliferation, invasion, and545
in cancer progression in general [85]. Gain of 7p12546
band has been associated with gain of EGFR gene as in547
squamous cell carcinoma of the lung [86] and gastric548
cancer [87]. In melanoma, a study that used two dif-549
ferent cytogenetic approaches (FISH and aCGH) has550
found a frequent amplification of the region 7p12.3551
among melanoma samples [88]. Other studies that fo-552
cused on the expression level of EGFR on 7p12.3 in553
melanoma have shown a correlation between high ex-554
pression of EGFR and gain in copy number of this re-555
gion, which might explain the role of this amplification556
in development of malignant melanomas [89,90].557
The other region, 7p14.3, was reported with ampli-558
fication of just one gene, AAA1 NPSR1-AS1. Very lit-559
tle is known about this antisense RNA. However, these560
findings do not exclude the possibility that other genes561
located at 7p14 can be influenced by this gain of this562
region. An example, the gene NPSR1, a G protein cou-563
pled receptor, is also located on 7p14.3. Overexpres- 564
sion of this gene has been reported to activate some 565
cancer-related pathways [91]. 566
The importance of our results lies in showing a fo- 567
cal amplification of 7p12-p14 region in chromosome 568
7p as a statically significant copy number gain, instead 569
of showing a broad copy number change that encom- 570
passes the entire arm, which implies the importance of 571
this region on chromosome 7p in melanoma. 572
3.2. Deletions identified by GISTIC 573
8p23.2 574
This region was reported by GISTIC with the low- 575
est q value among all other deletions. Loss or de- 576
crease in copy number in chromosome 8p has been ob- 577
served in melanoma [4,25,26] and other cancers such 578
as prostate cancer [92] and breast cancer [93]. De- 579
spite the frequent deletion of this chromosomal arm 580
in melanoma, the molecular drivers of the 8p loss re- 581
main uncharacterized. Here, our study shows a min- 582
imal region of deletion within chromosome 8p. This 583
focal deletion of 8p23.2 harbors the tumor suppres- 584
sor gene CSMD1. Deletion of this minimal region 585
with the tumor suppressor gene CSMD1 has been re- 586
ported in many different cancers, including colorec- 587
tal cancer [94], liver cancer [95], ovary cancer [96], 588
and more common in the head and neck squamous cell 589
carcinoma (HNSCC) and correlates with poor prog- 590
nosis [97,98]. In melanoma, a recent study of Tang 591
et al. has reported that CSMD1 functions as a tumor 592
suppressor gene in melanoma cells. They found that 593
the level of CSMD1 mRNA and protein in melanoma 594
cells was lower than in normal skin cancer. Also, they 595
showed that CSMD1 expression decreased prolifera- 596
tion and migration, and increased apoptosis and G1 ar- 597
rest in A375 melanoma cells in vitro. Furthermore, the 598
survival rate of mice with tumors expression CSMD1 599
was significantly higher than mice with tumors that 600
did not express CSMD1. Moreover, the study showed 601
that CSMD1 exhibits antitumor activity through ac- 602
tivation of Smad pathway [99]. That study and our 603
study provide CSMD1 as a candidate biomarker gene 604
in melanoma. 605
4p16.3 606
Deletion of the short arm of chromosome 4 is com- 607
mon in several cancers including breast cancer [100], 608
colon cancer [101], gastric cancer [102], and lung can- 609
cer [103]. However, deletion of this chromosomal arm 610
does not seem to have been observed preivously in 611
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melanoma. Yet, loss of the chromosome 4 has been re-612
ported in melanoma before [4]. In this study, a novel613
minimal deletion of the 4p16.3 telomeric region was614
identified. This region spanning 1.05 Mb included 26615
genes, 6 of which are zinc finger genes. An interesting616
gene that is also mapped to this region is the atypical617
fibroblast growth factor receptor (FGFRL1). Deletion618
or LOH of the FGFRL1 has been investigated inten-619
sively in bladder cancer, where a recent study [104] has620
investigate the role of FGFRL1 as a candidate tumor621
suppressor in cancer. The reasons that were proposed622
to consider FGFRL1 as a candidate tumor suppressor623
were that FGFRL1 acts as a decoy receptor prevent-624
ing activation of conventional FGFRs due to its lack of625
the intracellular tyrosine-kinase domain, also it inter-626
acts with the negative regulator of the MAPK signal-627
ing pathway SPRED1, and it is ability to promote cell628
adhesion by promoting cell adhesion and could there-629
fore prevent tumor development and spreading by en-630
hancing cell-cell adhesion and inhibiting invasion and631
metastasis [104]. Moreover, FGFRL1 has been shown632
to be down regulated in ovarian tumor [105] and to re-633
duce cell proliferation in response to FGF2 when ec-634
topically expressed in the ostecosarcoma cell line MG-635
63 [104].636
6q26637
Loss of the long arm of chromosome 6 is well-638
known genetic alteration in melanoma [4–6,25,26].639
Yet, few drivers have been pinpointed in this region640
of loss. One of the melanoma biomarkers in this chro-641
mosomal arm is MYB (6q23) that is used in FISH642
assays [7]. Here, rather than detecting the broad loss643
of the chromosome 6q that is known in melanoma, a644
high significant of deletion in a narrow region was de-645
tected (in fact, the broad deletion of 6q was reported646
in the GISTIC figure, but another higher and smaller647
peak emerged from that broad deletion, which is 6q26,648
indicating that this small deletion is the most signif-649
icant minimal deletion in 6q). This region 6q26 con-650
tains the tumor suppressor gene PARK2. Inactivation651
of PARK2 due to copy number loss has been iden-652
tified in various human cancers including esophageal653
adenocarcinoma, glioma, non-small cell lung cancer,654
lung adenocarcinoma, ovarian cancer, pancreatic ade-655
nocarcinoma, and in skin cutaneous melanoma (3.5%)656
(reviewed in [106]). The copy number loss is the pri-657
mary mode of alteration that inactivates PARK2 [107].658
This gene was studied as an important tumor suppres-659
sor gene for several reasons. First, its frequent deletion660
in many cancers, as was mentioned above. Second, it661
is involvement in many crucial cellular processes and 662
pathways, such as controlling cell cycle progression. 663
A study on a large group of tumors has reported the 664
PARK2 as master regulator of G1/S cyclins, where it 665
mediates the coordination of different classes of cy- 666
clins and therefore regulates the cell cycle. The study 667
showed that PARK2 targets cyclin D and cyclin E for 668
degradation, therefore inactivation of PARK2 results 669
in the accumulation of cyclin D and acceleration of 670
cell cycle progression [107]. Moreover, the mRNA and 671
the protein expression of PARK2 have been shown to 672
be downregulated in many different cancers, and the 673
low mRNA expression correlates with increased lymph 674
node metastasis, higher tumor grade, and worse overall 675
survival in ccRCC [106]. 676
The other gene that was reported in this narrow 677
deletion is PACRG, which is located 670 bp upstream 678
of PARK2 and transcribed from the opposite DNA 679
strand. PACRG has been shown to be downregulated in 680
leukemias, glioblastoma, and astrocytic tumors [108]. 681
A study on ccRCC has reported that the mRNA and 682
protein expression of PACRG and PARK2 together 683
was significantly downregulated compared with the 684
nonmalignant tissue [108]. 685
So, this focal deletion in our study, different than 686
the large deletion of chromosome 6q that is frequently 687
detected in melanoma, seems to be important in cancer 688
development. 689
11q13.1 690
Deletion of chromosome 11q is commonly known 691
in melanoma [4,23,25,109] and other types of can- 692
cers such as breast cancer [110], lung cancer [111], 693
and neuroblastoma [112]. Different studies and biolog- 694
ical evidences support the existence of melanoma tu- 695
mor suppressor genes on chromosome 11q, and dele- 696
tion of this chromosome in melanoma has been re- 697
ported to be associated with advanced tumor stage, 698
younger age at presentation, poorer prognosis, and 699
metastasis to the brain [109]. In our study, a focal dele- 700
tion of ∼94 kb region was defined in this chromoso- 701
mal arm. This narrow region contains the ovarian tu- 702
mor domain-containing Ub aldehyde-binding protein 703
1 (OTUB1). OTUB1 is expected to play broad func- 704
tions in cells [113]. However, a recent study has shown 705
that Otub1 is positive regulator of the tumor suppres- 706
sor p53 [114]. The study showed that Otub1 plays a 707
critical role in p53 stabilization and activation in cells 708
in response to DNA damage, and that through suppres- 709
sion the MDM2-mediated p53 ubiquitination. Further, 710
overexpression of Otub1 results in marked apoptosis 711
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and inhibition of cell proliferation in a p53-dependent712
manner. Also, Inhibition of Otub1 markedly impaired713
p53 activation induced by DNA damage [114]. There-714
fore, a recent review article concluded that Otub1 may715
act as a tumor suppressor, and more studies are needed716
to determine if Otub1 is downregulated in human can-717
cers [113].718
2p21719
This deletion centered on the gene PKDCC, which720
has a developmental role [115] but no suspected sig-721
nificance in cancer. It also overlaps a portion of a long722
noncoding RNA LOC102723824, which has not been723
characterized. Interestingly, this region includes the724
first exon of EML4. Multiple fusion products of EML4725
and ALK have been characterized in non-small cell726
lung cancer [116–119].727
5q35.3728
Although several genes fall within this region, few729
may be of interest in cancer. SQSTM1 is an activator730
of NF-κB [120], which plays a complex role in cancer731
etiology. It is thought that early inhibition of NF-κB732
may help cancer cells evade the immune system, al-733
though late inhibition is known to promote cancer cell734
survival [121].735
Deletions on chromosome 5 do not seem to be com-736
mon genetic alterations in melanoma. One study has737
observed deletion of chromosome 5q in melanoma,738
but indicated that deletion of this chromosome has not739
been associated with harboring any putative TSGs in740
melanoma [33]. However, loss of this region (5q35.3)741
has been reported in a number of tumors such as742
non-small cell lung carcinoma [122], and breast tu-743
mors [123], which implies the potential importance of744
genes within these region in cancer development.745
6p22.1746
Deletion of chromosome 6p has been reported in747
various types of tumors [124]. Yet, this is not true748
in melanoma, where amplification of this chromoso-749
mal arm is well known, as mentioned above. How-750
ever, here, a very narrow focal deletion was reported,751
spanning only one gene, MAS1L. This deletion does752
not overlap with the amplified region that was re-753
ported here (6p24.3). Interestingly, homozygous dele-754
tion at 6p22.1 has been shown in different cancers such755
as gliomas [124] and high frequent LOH of this re-756
gion was reported in cervical cancer [125]. Although757
MAS1L does not seem to have a known role in tu-758
morgenesis, frequent deletion of this region in differ-759
ent cancers suggest a potential importance for genes in760
this region.761
5p15.33 762
As was mentioned above, deletions on chromosome 763
5 in melanoma are not common. However, here, a 764
very interesting minimal region of deletion was iden- 765
tified on the chromosome 5p. Since deletion or LOH 766
of 5p15 is common in different cancers [126], sev- 767
eral studies aimed to identify the minimal deletion of 768
this region. A study on sporadic gastric carcinomas 769
found high frequent LOH at 5p15.33, and an obvious 770
genotype-phenotype correlation on 5p15.33 was ob- 771
served [127]. Moreover, other studies on cervical car- 772
cinoma and sporadic colorectal cancer have reported 773
5p15.3 as the minimal deletion on 5p [128,129]. Fur- 774
ther, 5p15.3 has been proposed to contain one or more 775
tumor suppressor genes [126]. In our study, this narrow 776
region (1.05 Mb) was reported harboring 18 genes, 3 of 777
which are important putative tumor suppressor genes 778
AHRR, SDHA, and NKD2. 779
ARHH: a study has reported AHRR as a tumor 780
suppressor gene in multiple human cancers. This 781
study found a consistent downregulation of AHRR 782
mRNA in human malignant tissue from differ- 783
ent origins including colon, breast, lung, stomach, 784
cervix and ovary. Moreover, they found that silenc- 785
ing of ARHH enhances tumor growth in vitro and 786
in vivo through deregulation in cell cycle control 787
and protects against apoptosis and enhances angio- 788
genic potential, migration and invasion in tumor 789
cells. Furthermore, ectopic expression of AHRR 790
resulted in growth inhibition and reduced angio- 791
genic potential. The study concluded that AHRR 792
plays an important role in suppressing tumor for- 793
mation in humans [126]. 794
SDHA: a study on paraganglioma “known with 795
RET mutation” has reported SDHA as a tumor 796
suppressor gene. SDHA is not well studied, but 797
the study, through immunohistochemistry and tran- 798
scriptome analysis, indicated that SDHA acts as 799
a tumor suppressor gene through activation of a 800
pseudo-hypoxic pathway [130]. 801
NKD2: in a very recent study on osteosarcoma 802
(OS), NKD2 was shown to be a negative regula- 803
tor of WNT signaling pathway. The study showed 804
that decreased expression of NKD2 is associated 805
with highly aggressive OS state. Also, overexpres- 806
sion of NKD2 in metastatic human and mouse OS 807
cells significantly decreases cell proliferation, mi- 808
gration, and invasion ability in vitro and signifi- 809
cantly diminishes OS tumor growth and metastasis 810
in vivo. Therefore, the study showed NKD2 as a 811
novel suppressor of OS tumor growth and metasta- 812
sis in both mouse and human [131]. 813
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16q23.3814
Loss of chromosome 16q, and particularly 16q23815
has been reported in different cancers [132–134]. In816
melanoma, different studies have shown loss of chro-817
mosome16q [6,135]. Moreover, a CGH study on pri-818
mary and metastatic melanoma has reported the loss of819
this minimal deletion of 16q23, but no gene was spec-820
ified in this region [136]. In our study, chromosome821
16q was reported with a focal deletion centered at the822
16q23.3 band. This narrow region harbors the putative823
tumor suppressor gene CDH13, and two non-coding824
genes has-mir-3180 and miR-3182. The involvement825
of CDH13 in various cancers was reviewed recently826
by Andreeva and Kutuzov [137]. Downregulation of827
CDH13 has been reported in broad range of cancers,828
including melanoma cell lines, and nondetection of829
CDH13 transcript in all examined breast cancer and830
most other cancer cell lines supports its role as a tumor831
suppressor. Further, the review discussed association832
between downregulation of CDH13 and poor prog-833
nosis in various carcinomas. CDH13 re-expression in834
most cancer cell lines inhibits cell proliferation and in-835
vasiveness, increase susceptibility to apoptosis, and re-836
duce tumor growth in vivo models. Reporting this min-837
imal deletion containing CDH13 as the most signif-838
icant loss in chromosome 16q across the melanoma839
samples might imply the importance of this gene in840
melanoma tumorgenesis.841
17q11.2842
This is a well-known frequent region of deletion in843
different cancers, and that because it harbors the fa-844
mous tumor suppressor gene NF1, the RAS inhibitor.845
NF1 is the gene that encodes RAS GTPase-activating846
protein, so affecting this gene by deletion or mutation847
affects RAS-MAPK signaling. NF1 has been reported848
to work as a tumor suppressor in melanoma [138].849
Loss of NF1 function in melanoma has been shown in850
several studies [139–141]. These findings confirm the851
frequent inactivation of the NF1 tumor suppressor in852
melanoma.853
12q24.31854
This is focal deletion was reported on chromo-855
some 12q, which has been found to be amplified in856
melanoma [23]. Yet, this particular region of deletion857
(12q24) has also been reported in melanoma [136,858
142], which indicated the tendency of this region to859
be lost in melanoma cells. In our results, this mini-860
mal deletion was reported containing NCOR2 gene.861
Interestingly, NCOR2 (also known as SMRT) is a tu-862
mor suppressor that has been reported in different can- 863
cers. SMRT was shown to be involved as a novel tumor 864
suppressor in non-Hodgkin lymphomas [143]. Also, 865
down-regulation of SMRT in multiple myeloma has 866
been shown to jeopardize several gene functions that 867
play an important role in apoptosis, therefore, restora- 868
tion of SMRT activity might correct the overexpression 869
of antiapoptotic genes [144]. Lastly, a recent study has 870
reported that SMRT is an activator of p53 transcrip- 871
tion [145]. 872
20q11.21 873
Here, a very short region of deletion in the chro- 874
mosome 20q was reported. This short deletion con- 875
tains just one gene called BPIFB1, known also as 876
LPLUNC1. Recent studies have reported this gene as 877
an important tumor suppressor gene in NPC (Nasopha- 878
ryngeal Carcinoma) [146]. The study reported that 879
LPLUNC1 inhibited NPC cell proliferation in vitro 880
and tumor formation in vivo. LPLUNC1 also delayed 881
cell cycle progression from G1 to S phase and inhibited 882
the expression of cyclin D1, cyclin-dependent kinase 883
4 (CDK4) and phosphorylated Rb. LPLUNC1 inhib- 884
ited the expression of certain mitogen-activated pro- 885
tein (MAP) kinases (MAPK) kinases and cell cycle- 886
related molecules. Western blotting confirmed that the 887
expression of MEK1, phosphorylated ERK1/2, phos- 888
phorylated JNK1/2, c-Myc and c-Jun were inhibited by 889
LPLUNC1, suggesting that the MAPK signaling path- 890
way is regulated by LPLUNC1 [146]. Another study 891
reported that LPLUNC1 inhibist NPC cell proliferation 892
through inactivation Stat3. Induction of LPLUNC1 893
overexpression inhibited NPC cell proliferation, in- 894
duced NPC cell arrest, promoted NPC cell apoptosis 895
even after IL-6 stimulation, and inhibited the growth 896
of implanted NPC tumors in vivo, which were associ- 897
ated with decreasing cyclin D1 and Bcl-2 expression 898
and the Janus kinase 2 (JAK2)/Stat3 activation, but en- 899
hancing Bax and p21 expression [147]. 900
6q14.1 901
The gene SH3BGRL2 is a paralog to SH3BGRL. 902
While the latter has been shown to contribute to Rel- 903
mediated transformation when inactivated [148], so 904
such role has yet been identified in the former. 905
10q23.2 906
10q is a known deletion in melanoma [4]. Loss of 907
10q23 is common in melanoma and loss of this re- 908
gion (more specifically 10q23.3) has been associated 909
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with inactivation of the tumor suppressor gene PTEN910
in melanoma [4,149,150].911
This region also contains the last exon of WAPAL,912
a gene which is a component of the cohesin complex.913
Loss of WAPAL function potentially prevents the re-914
lease of cohesin from sister chromatids [151] or inter-915
feres with DNA repair [152].916
5q35.1917
Only one gene was reported at this focal deletion,918
which is the potassium channel subfamily M regula-919
tory beta subunit 1, KCNMB1. There is no known im-920
portance of this gene in oncogenesis. However, this921
region has been reported to be frequently deleted in922
lung cancer, indication the presence of important genes923
with tumor suppression function at this region [122,924
153,154].925
16p13.3926
Deletion of 16p has been reported in melanoma [26,927
155]. Here, a small (∼752 Kb) telomeric deletion that928
contains 40 genes. Here, at least two known tumor sup-929
pressors can be identified, AXIN1 and ARHGDIG.930
AXIN1 is a WNT pathway tumor suppressor that is931
essential for beta catenine degradation, and it is inac-932
tivation has reported in various tumors [156,157]. Fur-933
thermore, AXIN has been shown to act as a tumor sup-934
pressor through stimulating p53 function [158].935
ARHGDIB: is a metastasis suppressor that has been936
shown to contribute to cancer cell invasion and metas-937
tasis, and also has been shown to be involved in mouse938
melanoma B16 cells [159].939
13q13.3940
Deletion of this particular region 13q13.3 has been941
reported in different cancers such as breast cancer [160,942
161], and lung cancer [162]. Here, this region was re-943
ported with one gene DCLK1. Some studies have re-944
ported deletion of this region with this gene such as945
in testicular primary seminoma [163], and in pleomor-946
phic sarcoma of bone [164]. A study on melanoma has947
reported a large deletion of 13q12-34 [135].948
3q13.31949
ZBTB20 is involved in NF-κB signaling and pro-950
motes the innate immune response [165] (cf. SQSTM1951
also deleted). It is also a negative regulator of952
Sox9 [166]. Sox9 has been shown to induce cell cy-953
cle arrest and apoptosis in melanoma via antagonism954
of Sox10 [167]. Therefore, deletion of Sox9 has the955
potential to promote melanoma initiation and progres-956
sion.957
10p15.3 958
Loss of 10p15.3 is a common deleted region in 959
different cancers including colorectal cancers [168] 960
and lung cancer [153]. In melanoma, loss of 10p is 961
common genetic alteration (with loss of 10q as well 962
as loss of the whole chromosome) [4,33,169]. Mi- 963
croarrays studies on melanoma have reported dele- 964
tion of 10p15.3 [33,150]. In our study, this region 965
of deletion was reported with the RNA editing en- 966
zyme gene ADARB2. ADARB2 RNA level has been 967
reported to be 99% decreased in brain tumors and 968
ADARB2 reduction correlates with grade of malig- 969
nancy of glioblastoma multiforme, the most aggressive 970
of brain tumors [170]. 971
3p22.1 972
This is a very narrow deletion centered at the gene 973
VIPR1. This region of deletion is common in non- 974
small cell lung cancer [171]. VIPR1has been reported 975
to be a tumor suppressor in lung adenocarcinoma, 976
where it is significantly downregulated, and deletion of 977
3p22 is the mechanism that leads to its downregula- 978
tion [172]. 979
1p32.3 980
This deletion encompasses the entire gene ACOT11, 981
a lipid transfer protein. ACOT11 has been shown 982
to be significantly methylated in bladder cancer, and 983
the degree of methylation was associated with tu- 984
mor stage [173]. Any specific biological function of 985
ACOT11 in cancer remains to be determined. 986
11p15.4 987
This region is adjacent to a domain on 11p15.5 988
known to play a role in Wilms and rhabdomyosar- 989
coma [174], adrenocortical carcinoma [175], and 990
lung [176], ovarian [177] and breast cancers [178]. 991
Interestingly, 11p has been reported with reduced 992
copy number in melanoma [25]. 993
21q22.3 994
Loss of 21q22.3 has been shown to be associated 995
with melanoma [179]. Within this large deletion, the 996
transient receptor potential channel gene TRPM2 has 997
been shown to increase the susceptibility of melanoma 998
to apoptosis and necrosis [180]. An antisense tran- 999
script of TRPM2 is up-regulated in melanoma (ibid). 1000
Intriguingly, the related gene TRPM1 (melastatin, at 1001
15q13.3) has been known to be downregulated in 1002
highly metastatic melanoma [181]. 21q22.3 deletion is 1003
also observed in prostate cancer [182]. 1004
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18p11.311005
Here, only one gene was reported, LAMA1. It is1006
one of the genes that encode laminins, which are ma-1007
jor proteins in the basal lamina. They influence cell1008
differentiation, migration, and adhesion. Also they can1009
play a role in invasive behavior of tumor cells [183].1010
LAMA1 has been reported to be hypermethylated and1011
underexpressed in pancreatic tumor samples compared1012
to normal samples [184]. Moreover, downregulation1013
of LAMA1 has been reported in ovarian cancer cell1014
lines [183].1015
1q21.31016
This deletion is almost exclusive to the gene KCNN31017
(SK3). This potassium channel is better known for1018
its role in neuron firing, but it has also been shown1019
to play a role in the motility of breast cancer [185]1020
and melanoma [186] cells. It was shown that KCNN31021
was not expressed in normal melanocytes, but that in-1022
duced expression of KCNN3 in melanoma cells in-1023
creased migration. This work was done in cultured1024
melanoma cell lines; the frequency of SK3 overexpres-1025
sion in melanoma is unknown in situ, but our data1026
would suggest that SK3 overexpression could be an ar-1027
tifact of cell culture.1028
2p211029
This deletion includes the last exon of PPM1B.1030
PPM1B is thought to act as a phosphatase toward1031
IKKβ, thereby attenuating the activity of NF-κB [187].1032
This locus as a whole is involved in 2p21 Deletion Syn-1033
drome (OMIM #606407), which is not known to con-1034
tribute to an elevated prevalence of any cancers.1035
9p21.31036
Although deletion of chromosome 9 was also re-1037
ported in our result, a more focused deletion was1038
also reported in chromosome 9 centered at 9p12.3.1039
This region contains the well-known tumor suppres-1040
sor gene CDKN2A, and other tumor suppressors such1041
as CDKN2B, MTAP and ELAVL2. CDKN2A is the1042
one of the highest-penetrance melanoma suscepti-1043
bility gene [188,189] and it is deletion or loss of1044
expression in melanoma is well-known [188–191].1045
As was mentioned above, other important genes are1046
also located in this region. CDKN2B is one of the1047
genes located at 9p21 and has been shown to be1048
deleted in melanoma [6,192] and other cancers such1049
as cutaneous T-cell lymphoma [193]. Interestingly,1050
codeletion of a cluster of genes involving CDKN2A,1051
CDKN2B, MTAP and in some cases ELAVL2 has been1052
shown in different cancers. For instance, deletion of 1053
CDKN2A, CDKN2B, MTAP and ELAVL2 in myeloid 1054
leukemia [194] and CDKN2A, CDKN2B and MTAP 1055
in B- lineage acute lymphoblastic leukemia [195], head 1056
and neck squamous cell carcinoma [196], mesothe- 1057
liomas [197] and in glioblastoma [198]. Deletion of 1058
this large 9p21 segment is a frequent genetic alteration 1059
in variety of cancers causing inactivation of critical tu- 1060
mor suppressor genes and therefore plays a very im- 1061
portant role in development of many human cancers, 1062
including melanoma [199,200]. Our results confirm the 1063
frequent involvement of 9p21 deletion in melanoma 1064
samples. 1065
However, 9p21 is not a high discriminatory loci, 1066
where it is heterogeneous deletion can also be seen 1067
not just in melanoma but in melanocytic nevi as well. 1068
In contrast, homozygous deletion of 9p21 seems to be 1069
more unique to melanoma [201,202]. 1070
22q13.32 1071
This deletion encompasses over 150 annotated 1072
genes, and is frequently deleted in human breast and 1073
colon cancers [203]. Within this region are at least 1074
three genes with some demonstrated connection to 1075
cancer: BIK, PRR5, and PANX2. BIK is an impor- 1076
tant player in the activation of Bax to induce apop- 1077
tosis, and has been found to be deleted in several 1078
human cancers [204]. Interestingly, overexpression of 1079
Bik induces apoptosis in melanoma cells, and BIK 1080
expression in a xenograft model delayed melanoma 1081
tumor growth [205]. PRR5 is suspected tumor sup- 1082
pressor gene in breast cancer [203] and a compo- 1083
nent of mammalian target of rapamycin complex-2 1084
(MTORC2) [203] although little is known about its 1085
function. PANX2 acts as a tumor suppressor in glioma 1086
cells [206]. The related pannexin family members 1087
PANX1 and PANX3 show reduced expression in basal 1088
and squamous cell carcinomas [207]; however, PANX1 1089
may be a driver of melanoma [208]. Much remains to 1090
be understood about how these pore channel proteins 1091
play roles in tumorigenesis. 22q13.32 has also been 1092
found deleted in 25% of fibrolamellar hepatocellular 1093
carcinomas [209]. 1094
2q33.2 1095
Two caspases falls into this region. CASP8 lies just 1096
downstream of death receptors in the cell-extrinsic 1097
apoptosis pathway. As such, it has been found to be 1098
mutated or lost in many cancers (reviewed in [210]). 1099
CASP10 mutation has been observed in gastric can- 1100
cer [211] and non-Hodgkin’s lymphoma [212]. 1101
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Fig. 1. Focal amplifications determined by GISTIC. Chromosome position is arranged along the x-axis and GISTIC q-value is shown on the
y-axis. The default cutoff of 0.25 for genes discussed here is indicated in green. The locations of genes not specifically implicated as gained in
melanoma previously are depicted in bold.
Fig. 2. Focal deletions determined by GISTIC. Chromosome position is arranged along the x-axis and GISTIC q-value is shown on the y-axis.
The default cutoff of 0.25 for genes discussed here is indicated in green. The locations of genes not specifically implicated as lost in melanoma
previously are depicted in bold.
RAPH1, also found within this deletion, has been1102
observed as lost in oral squamous cell carcinoma [213],1103
head and neck squamous cell carcinoma [214], esopha-1104
geal squamous cell carcinoma [215], lung cancer [216],1105
and neuroblastoma [217]. Reduced expression of1106
ABI2, also found in this region, is observed in breast1107
and ovarian cancers [218]. Many studies have reported1108
ABI2 as a tumor suppressor, where Abi2 promotes1109
Abl-mediated phosphorylation of Cdc2 and inactiva-1110
tion of Cdc2 kinase activity, leading to suppression of1111
cell growth [219,220].1112
13q34 1113
This deletion has been observed previously in sev- 1114
eral cancers, but not to our knowledge in melanoma. 1115
Notably, 13q34 is lost in 45% of cutaneous anaplas- 1116
tic large cell lymphoma [221], 67% of chronic lym- 1117
phocytic leukemias [222], and 8% of Burkitt lym- 1118
phomas [223]. It has also been noted missing in some 1119
cervical squamous cell carcinomas [224–226], breast 1120
cancer cases showing centrosome abnormalities [227], 1121
one case of chronic lymphocytic leukemia [228], 1122
esophageal squamous cell carcinoma [229], bladder 1123
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Table 2
Significant copy number variation. Regions of variation are ordered by q-value (an upper bound on the expected fraction of false positives).
Location of each CNV is given as genomic location and coordinates. The number of known genes within each region was determined from the
hg19 assembly of the human genome. Genes of interest (those known to play a role in cancer, or specifically in melanoma) are featured, and
references to the relevant studies are given in the Results section
Rank Genomic Peak GISTIC Gene Known in cancer Known in melanoma
location region q-value count
Amplifications
1 21q22.1 chr21:39861045-39866904 2.22E-7 1 ERG −
2 11q14.1 chr11:83358080-83366882 2.56E-7 1 DLG2 −
3 10q11.21 chr10:43622934-43623811 5.92E-4 1 RET −
4 6p24.3 chr6:1-22748031 1.17E-2 118 NEDD9, DEK, E2F3 6p, NEDD9, RREB1, DEK
5 7p14.3 chr7:34477091-34483332 1.17E-2 1 − 7p
6 1q31.2 chr1:114755790-249250621 1.30E-1 1206 AKT3,MDM4, ABL2 1q
7 8q24.23 chr8:99387730-146364022 1.30E-1 284 MYC MYC
8 7p12.3 chr7:46879412-46880294 1.30E-1 1 7p12 7p
Deletions
1 8p23.2 chr8:1986591-6269441 1.5489E-7 3 CSMD1 8p
2 4p16.3 chr4:1-1110173 1.74E-04 23 FGFRL1 −
3 6q26 chr6:161767520-163770210 1.74E-04 4 PARK2, PACRG 6q
4 11q13.1 chr11:63680046-63774300 1.74E-04 3 OTUB1 11q
5 2p21 chr2:42180913-42397164 2.03E-04 1 PKDCC, EML4 −
6 5q35.3 chr5:179219193-179388308 1.04E-03 6 SQSTM1 5q
7 6p22.1 chr6:29427138-29498496 1.36E-03 1 6p22.1 −
8 5p15.33 chr5:1-1054830 2.56E-03 18 SDHA, AHRR, NKD2 −
9 16q23.3 chr16:82658729-83542835 3.40E-03 3 CDH13 16q
10 17q11.2 chr17:29704122-29872630 7.98E-03 2 NF1 NF1
11 12q24.31 chr12:124452696-125266431 1.18E-02 4 NCOR2 (SMRT) 12q24
12 20q11.21 chr20:31830310-31946860 1.43E-02 1 BPIFB1 (LPLUNC1) −
13 6q14.1 chr6:80412926-80513550 2.10E-02 1 SH3BGRL2 6q
14 10q23.2 chr10:88278583-88520408 2.67E-02 2 WAPAL 10q
15 5q35.1 chr5:169759991-169932228 2.77E-02 1 − 5q
16 16p13.3 chr16:1-752680 2.80E-02 40 AXIN1, ARHGDIG 16p
17 13q13.3 chr13:36341439-36742905 3.05E-02 1 DCLK1 13q12-34
18 3q13.31 chr3:114054708-114463757 4.46E-02 3 ZBTB20 −
19 10p15.3 chr10:1208827-1601334 5.09E-02 2 ADARB2
20 3p22.1 chr3:42451413-42590432 5.27E-02 1 VIPR1 −
21 1p32.3 chr1:54870183-55085182 5.81E-02 1 ACOT11 −
22 11p15.4 chr11:3076258-3249828 5.81E-02 3 11p15.5 11p
23 21q22.3 chr21:45878481-48129895 5.81E-02 50 21q22.3 21q22.3
24 18p11.31 chr18:6929284-7231471 6.72E-02 1 LAMA1 −
25 1q21.3 chr1:154596123-154898074 7.09E-02 1 KCNN3 −
26 2p21 chr2:44460525-44590065 7.09E-02 3 PPM1B
27 9p21.3 chr9:20651454-25679201 7.09E-02 34 CDKN2A, CDKN2B CDKN2A, CDKN2B
28 22q13.32 chr22:41481652-51304566 7.09E-02 154 BIK, PRR5, PANX5 −
29 2q33.2 chr2:200814810-206486163 1.10E-01 45 RAPH1,CASP8, ABI2 −
30 13q34 chr13:109280035-115169878 1.47E-01 42 ING1, COL4A1, COL4A1 −
31 15q26.1 chr15:91642272-93012556 1.51E-01 3 SLCO3A1 −
32 Chr.9 chr9:1-141213431 1.91E-01 953 Chr.9 Chr.9
Table 3
Summary of broad and focal copy number variations
Broad chromosomal copy number Focal chromosomal copy number
Amplifications:
1q, 6p, 8q 7p12.3, 7p14.3,10q11.21, 11q14.1, 21.q22.1
Deletions:
2q33, all 9, 13q34, 15q26, 16p13, 22q13 1q21.3, 1p32.3, 2p21, 3q13.31, 3p22.1, 4p16.3, 5q35.1, 5q35.3, 5p15.33, 6q14.1, 6q26, 6p22.1,
8p23.2, 9p21.3, 10q23.2, 10p15.3, 11q13.1, 11p15.4, 12q21.31, 13q13.3, 15q26.1, 16q23.3,
17q11.2, 18p11.31, 20q11.21
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carcinoma [230], and cutaneous T-cell lympho-1124
mas [226]. Among the genes found in this region1125
are ING1, COL4A1, and COL4A2. ING1 is down-1126
regulated or lost in several cancers [231,232] ING11127
(Inhibitor of growth 1) is a well-known tumor sup-1128
pressor that is known to be involved in cell growth1129
control, apoptosis, cell proliferation, senescence, and1130
DNA replication and repair [232,233]. COL4A1 and1131
COL4A2 are suspected tumor suppressor genes [230].1132
15q26.11133
SLCO3A1, found here in its entirety, is another1134
known regulator of NF-κB [234] (along with PPM1B,1135
SQSTM1, and ZBTB20) deleted in our melanoma1136
specimens. Overexpression of SLCO3A1 was shown1137
to induce NF-κB transcriptional activity (ibid). It has1138
also been suspected of serving to transport anticancer1139
drugs out of the cell [235], but this has not been demon-1140
strated to our knowledge. Deletion of SLCO3A1 has1141
been observed in acute lymphoblastic leukemia [236].1142
Chromosome 91143
This peak (with the highest q value) represents loss1144
of the entire chromosome 9. The incidence of this ge-1145
netic alteration is frequent in bladder cancer [237,238].1146
CGH study on primary cutaneous melanoma by Bas-1147
tian et al. has reported the loss of chromosome 9 in1148
melanoma samples [26]. Moreover, another study on1149
sporadic and familial melanomas has shown the loss of1150
entire copies of chromosome 9 [239].1151
4. Conclusions1152
Here, we have compared melanoma to benign nevi1153
rather than to normal skin or controls taken from pe-1154
ripheral blood. The reasoning here is that the differ-1155
ences of interest are between the lesions being com-1156
pared for diagnostic purposes in the clinic. That is,1157
we are more interested in the cytogenetic differences1158
that may set apart an ambiguous melanoma from a1159
benign lesion than the differences between melanoma1160
and no lesion at all. This method does not, therefore,1161
detect nevus-associated copy number variation. In this1162
study we identified several important regions of ge-1163
nomic amplification (Fig. 1) and deletion (Fig. 2) in1164
melanoma. These are summarized in Table 2. Several1165
regions encompass broad areas of copy number vari-1166
ation (detailed in Table 3), but others represent more1167
focal events. Some of the affected genes in these re-1168
gions have previously identified roles in melanoma,1169
and more have been observed in various other cancers. 1170
Taken together, these results support much previous 1171
work in melanoma etiology and may serve to develop 1172
other diagnostic or therapeutic strategies for this dis- 1173
ease. 1174
GISTIC provided a robust and unbiased analysis to 1175
identify somatic copy number alterations in melanoma 1176
samples. The identified regions of aberrations repre- 1177
sent the most statistically significant differences be- 1178
tween the clinical melanoma and benign nevi speci- 1179
mens. Therefore, these results can be exploited to im- 1180
prove current diagnostic techniques and provide more 1181
sensitive methods to discriminate between problematic 1182
melanomas and benign nevi neoplasms. Currently, the 1183
most commonly used FISH assay employs a 4-probe 1184
panel targeting 4 loci (RREB1, MYB, centromere 6, 1185
and CCND1) on 2 different chromosomes. The 4- 1186
probes FISH has shown a sensitivity and specificity 1187
of 86.7% and 95.4% respectively [18]. Recent study 1188
has shown an improvement of the FISH assay by in- 1189
corporating new probes that target 4 different chromo- 1190
somes (CDKN2A on 9p21, RREB1 on 6p25, MYC on 1191
8q24 and CCND1 on 11q13) with increased sensitiv- 1192
ity and specificity to 94% and 98% respectively [7]. 1193
Due to the technical limitations of FISH, the justifica- 1194
tion for adding a locus to the analysis must overcome 1195
the consequences of removing another. CGH or aCGH 1196
itself, as here, could be developed as diagnostic tools 1197
for melanoma and indeed this is described in the lit- 1198
erature [21]. A third potential approach is the addition 1199
of CNV observed here to qPCR-based assays like the 1200
duplex ratio tests described by Moore et al. [240]. This 1201
has the advantage of being amenable to FFPE speci- 1202
mens and being imminently expandable to incorporate 1203
new loci. 1204
Moreover, GISTIC detected key genomic regions 1205
whose genes seem to play important roles in melanoma 1206
pathogenesis. Some of these novel identified genes (es- 1207
pecially in significant region of amplifications) are po- 1208
tential candidates for molecular targeted therapies. In 1209
fact, proposed therapies have been introduced target- 1210
ing some of the novel genes identified in our analysis, 1211
such as targeting the RET gene with small receptor ty- 1212
rosine kinase inhibitors in thyroid cancer (specifically 1213
for identified activating mutations in RET) and other 1214
cancers [241–243]. Another gene that is being targeted 1215
for cancer therapy is ERG transcription factor, the gene 1216
with the most significant copy number gain in our anal- 1217
ysis. Several studies have reported their attempts in de- 1218
veloping drugs that target the ERG transcription fac- 1219
tor, mostly in prostate cancer [244,245]. Further vali- 1220
dation of the results described here would suggest the 1221
expansion of such trials to include melanoma. 1222
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